On the day that I called her, a few weeks after the genomic sequencing of her cancerous tumor had been completed, I thought we would be discussing how participating in our tumor sequencing study had compared to her expectations. Sequencing tumors from patients like this woman, those for whom either the standard of care is ineffective or no standard of care exists, can inform choices regarding clinical trials or targeted therapy based on the molecular characteristics of the cancer. So, my planned questions focused on whether the patient’s results had changed her treatment or been helpful in any other way.
Zikmund-Fisher BJ. When “Actionable” Genomic Sequencing Results Cannot Be Acted Upon. JAMA Oncol. 2017;3(7):891–892. doi:10.1001/jamaoncol.2016.3283